[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"image\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:image":297},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,43,72,100,121,146,172,198,235,268],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100517411","ultrasound-for-socket-healing-evaluation-100517411",false,"NCT06017193","Ultrasound for Socket Healing Evaluation","Ultrasonic Imaging of Bone Graft Healing in Extraction Sockets for Precise and Personalized Implant Therapy (HUM00226516)","Inclusion Criteria:\n\n* Patients at least 18 years of age and have at least a tooth that is considered hopeless, planned for an extraction and a bone grafting procedure for subsequent dental implant surgery.\n\nExclusion Criteria:\n\n* Patients not willing or not able to have an extraction, bone graft and subsequent implant surgery due to health, finance, or any other reasons.",true,"ALL","18 Years",{"count":20,"type":21},140,"ESTIMATED","OBSERVATIONAL","The design is a single blinded, dual comparative study of ultrasound versus micro-CT\u002FLASCA in one study group. Up to a total of 140 subjects registered will be recruited. Subjects who are treatment planned for extraction of a hopeless tooth and socket augmentation with bone graft and are planned for a dental implant surgery. The socket will be evaluated before the extraction and multi-time points during healing until an implant is placed with various evaluation tools, including ultrasound.",[25,26,27,28,29],"Healing Wound","Alveolar; Wound","Alveolar Bone Loss","Image","Dent Disease","RECRUITING","2025-10-30",{"date":33,"type":34},"2025-10-31","ACTUAL",{"date":36,"type":34},"2024-07-25",{"date":38,"type":21},"2027-07-01",{"name":40,"class":41},"University of Michigan","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":5},"100573400","clinical-validation-of-bonemri-in-the-spine-100573400","NCT06745791","Clinical Validation of BoneMRI in the Spine","CleverBones","Inclusion Criteria:\n\n* ≥ 12 years old\n* Indication for diagnostic MRI of the spine\n* Indication for diagnostic CT of the spine\n* Eligible for MRI\n* Eligible for CT\n* Written informed consent\n\nExclusion Criteria:\n\n* Pregnancy\n* History of (psychiatric) disorder which causes the patient to be incompetent to make a thought-out decision\n* claustrophobia\n* \\>3 months between CT and MRI scan","12 Years",{"count":52,"type":21},450,"BoneMRI is a quantitative 3D MRI technique that has been developed recently by MRIGuidance BV©, which is based on a multiple gradient-echo sequence and a machine learning processing pipeline. The BoneMRI technology is capable of generating CT-like, quantitative radiodensity bone MRI images to visualize cortical and trabecular bone, allowing to assess bone structure and morphology, in addition to regular clinical MRI images. The use of BoneMRI has been investigated and clinically validated in multiple musculoskeletal studies involving the cervical spine, hip and sacro-iliac joint. In order to clinically use BoneMRI in the entire spine, the BoneMRI technology needs to be validated in that area as well, focussing on geometrical and voxelwise accuracy of the radiodensity contrast to assure accurate visualization of the osseous structures. As robustness against expected data variability between hospitals is crucial for successful machine learning algorithms, multiple MR field strengths and scanner types from different manufacturers will be included in this study. If successful, BoneMRI will facilitate a better, easier and cheaper workflow by enabling diagnosis, treatment planning and surgical navigation using a single radiological examination, without the potential hazards of ionizing radiation.",[55,28,56],"Bone Diseases","Medical Device",[58,59,60,61],"medical device","software","synthetic CT","MRI sequence","2025-09-23",{"date":64,"type":34},"2025-09-24",{"date":66,"type":34},"2021-08-20",{"date":68,"type":21},"2026-12-31",{"name":70,"class":71},"MRIguidance B.V.","INDUSTRY",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":83,"phases":84,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":42},"100492842","phase-1-hp-pyruvate-mri-in-cancers-100492842","NCT05697406","HP Pyruvate MRI in Cancers","Hyperpolarized 13-C Pyruvate MRI Surveillance of Multiple Cancers","HC-MRI","Inclusion Criteria:\n\nClinical tumor diagnosis\n\nPatients with pre-existing MR imaging appointments\n\nMust be able to undergo MR\n\nExclusion Criteria:\n\nNo tumor diagnosis","88 Years",{"count":82,"type":21},25,"INTERVENTIONAL",[85,86],"PHASE1","PHASE2","Many human diseases are characterized by their ability to alter existing metabolic pathways and interrupt cellular processes. Cancer exploits the Warburg effect and utilizes greater glucose than normal cells and within this process uses anaerobic respiration, leading to increased conversion of pyruvate to lactate. This can be exploited by hyperpolarized imaging. Hyperpolarized 13C MRI imaging is an approach that utilizes a stable isotope of Carbon (13C) linked to pyruvate. MRI spectroscopy is used in conjunction with hyperpolarized 13C pyruvate in order to temporally detect pyruvate and its conversion to lactate in-vivo, in order to visualize downstream metabolic (glycolytic) activity secondary to the Warburg effect, which should be useful in detecting and characterizing tumors of various types. Hyperpolarized 13C pyruvate MR imaging has not been tested in most cancers. In this preliminary survey, we will test the hypothesis that hyperpolarized 13C pyruvate MR imaging can be used to image various cancers.",[28,89,90],"Warburg Effect","Tumors","2025-09-16",{"date":93,"type":34},"2025-09-22",{"date":95,"type":34},"2024-06-24",{"date":97,"type":21},"2028-12-01",{"name":99,"class":41},"University of Maryland, Baltimore",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":42},"100596005","aaa-cta-cohort-registry-100596005","NCT07039825","AAA-CTA Cohort Registry","Abdominal Aortic Aneurysm CTA Cohort Study (AAA-CTA Registry)","Inclusion Criteria:\n\n1. Patients with abdominal aortic aneurysm who visited the study hospital.\n2. Patients included should have computed tomography angiography data.\n\nExclusion Criteria:\n\n1\\. Patients who declined participation, cases with incomplete or missing clinical data.",{"count":108,"type":21},1000,"The aim of this study is to investigate the measurement of abdominal aortic aneurysm by computed tomography angiography. The research will collected the results of computed tomography angiography from inpatient, emergency, and outpatient populations with abdominal aortic aneurysm.",[111,28],"Abdominal Aortic Aneurysm","2025-06-18",{"date":114,"type":34},"2025-06-26",{"date":116,"type":34},"2020-01-01",{"date":118,"type":21},"2027-05-01",{"name":120,"class":41},"RenJi Hospital",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":130,"conditions":131,"keywords":134,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":145},"100553713","imaging-quality-and-potential-clinical-relevance-of-phase-contrast-mammography-in-vivo-a-single-center-prospective-study-100553713","NCT06489665","Imaging Quality and Potential Clinical Relevance of Phase Contrast Mammography In-vivo: a Single-center, Prospective Study","Imaging Quality and Potential Clinical Relevance of Phase Contrast","Inclusion Criteria:\n\n* Inclusion criteria -Phase 0:\n\n  * \\>18 years\n  * Mastectomy, tumorectomy or biopsy planned\n  * Informed consent of the patient\n\nInclusion criteria -Phase 1:\n\n* \\>18 years\n* BI-RADS 5 (highly suggestive of malignancy at ultrasound or mammography) or 6 (known biopsy proven malignancy);\n* Scheduled for mastectomy or breast conserving surgery with radiotherapy.\n* Informed consent of the patient\n\nInclusion criteria - Phase 2:\n\n* \\>40 years\n* undergoing mammography for screening or diagnostic purpose.\n* Informed consent of the patient\n\nExclusion Criteria:\n\n* Exclusion criteria for all three Phases:\n\n  * Breast implants. The women will be asked, if they have a breast-implant.\n  * Inability to understand the study procedure due to cognitive or linguistic deficits.\n\nExclusion criteria for patients, participating in Phase 1 and Phase 2:\n\n* Pregnancy\n* Breast-feeding.\n* Re-staging after neoadjuvant chemotherapy. Patients who participated in prior research projects with ionizing radiation in the past 12 months",{"count":129,"type":21},350,"Conventional mammography, breast sonography and breast MRI have specific weaknesses. In particular, mammography has a low sensitivity for the detection of mammary carcinoma in patients with a dense breast. Phase contrast mammography could help to overcome some of these limitations. Observational study.",[132,133,28],"Breast Cancer","Microcalcification",[135],"Mammography","2025-02-02",{"date":138,"type":34},"2025-02-05",{"date":140,"type":34},"2024-10-17",{"date":142,"type":21},"2030-09-01",{"name":144,"class":41},"University of Zurich",2,{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":17,"minAge":153,"maxAge":154,"enrollmentInfo":155,"targetDuration":156,"studyType":22,"phases":4,"briefSummary":157,"conditions":158,"keywords":160,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":171},"100557172","study-on-multimodal-imaging-and-molecular-imaging-techniques-in-degenerative-dementia-100557172","NCT06534658","Study on Multimodal Imaging and Molecular Imaging Techniques in Degenerative Dementia","MIMI","Inclusion Criteria:\n\n* Patients aged ≥50 and ≤85 years old, male or female;\n* Meet the diagnostic criteria for dementia or MCI;\n* Neuropsychological score: MMSE 15-28 points, CDR ≤ 1 point; ④ Patients and their families are informed and sign the informed consent form\n\nExclusion Criteria:\n\n* The presence of other neurological diseases that may cause brain dysfunction (such as depression, brain tumors, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.);\n* The presence of other systemic diseases that may cause cognitive impairment (such as liver dysfunction, renal dysfunction, thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.);\n* Suffering from a disease that makes it impossible to cooperate with cognitive examinations;\n* The presence of contraindications to MRI;\n* The presence of mental and neurological retardation;\n* Refusing to draw blood;\n* Refusing to sign the informed consent form.","50 Years","85 Years",{"count":108,"type":21},"5 Years","This project is a multicenter observational study that establishes a longitudinal cohort of patients with Alzheimer's disease and other dementias based on neuroimaging, molecular imaging, biological and digital markers to explore new solutions such as dementia disease mechanism, diagnosis, condition evaluation, and prognosis assessment.",[159,28],"Alzheimer Disease",[159,161],"molecular imaging","2024-07-30",{"date":164,"type":34},"2024-08-02",{"date":166,"type":34},"2020-07-30",{"date":168,"type":21},"2029-08-30",{"name":170,"class":41},"Ruijin Hospital",8,{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":179,"minAge":18,"maxAge":180,"enrollmentInfo":181,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":183,"conditions":184,"keywords":187,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":42},"100557099","satisfactory-debulking-prediction-model-for-advanced-ovarian-cancer-based-on-pet-ct-image-data-100557099","NCT06533709","Satisfactory Debulking Prediction Model for Advanced Ovarian Cancer Based on PET-CT Image Data","Satisfactory Debulking Prediction Model for Advanced Ovarian Cancer Based on PET-CT Image Data and Its Clinical Application","Inclusion Criteria:\n\n* Pathological type is epithelial ovarian cancer.\n* Underwent primary debulking surgery at our hospital.\n* Postoperative pathological staging is FIGO stage IIB or above.\n* Clinical, surgical, and pathological data of the patient are mostly complete.\n\nExclusion Criteria:\n\n* Pathological type is non-epithelial ovarian cancer.\n* Underwent fertility-preserving surgery or palliative surgery.\n* Presence of infection during PET\u002FCT image acquisition.\n* Concurrent other malignant tumors.\n* Severe diseases of other major organs.","FEMALE","80 Years",{"count":182,"type":21},146,"This project intends to conduct a multicenter retrospective study to evaluate the satisfactory reduction of advanced ovarian cancer using PET-CT images, and explore the correlation between molecular biological characteristics and clinical characteristics of ovarian cancer through high-throughput sequencing genomics combined with radiomics.",[185,28,186],"Ovarian Cancer","Predation",[185,188,189],"PET-CT Image","Debulking Prediction Model",{"date":191,"type":34},"2024-08-01",{"date":193,"type":34},"2024-06-01",{"date":195,"type":21},"2026-05-31",{"name":197,"class":41},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":208,"conditions":209,"keywords":215,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":234},"100473535","biomel--diagnostic-and-prognostic-factors-in-melanoma-100473535","NCT05446155","BioMEL- Diagnostic and Prognostic Factors in Melanoma.","BioMEL - a Translational Study About Aetiology, Diagnosis, Prognosis, Treatment, Biology and Biomarkers in Clinically Atypical Nevi and Melanoma.","BioMEL","Inclusion Criteria:\n\n* Primary part of the project: Patients in dermatological outpatient routine care in Helsingborg, Lund or Malmö Hospitals. Patients are planned for surgical excision for an equivocal pigmented skin lesion that could be a primary melanoma or a differential diagnosis of melanoma\n* Secondary part of the project: . Patient, in surgical or oncological routine care in Helsingborg, Lund, Malmö or Kristianstad Hospitals. Patients are planned for surgical excision or cytological diagnostics (needle aspiration) of metastatic melanoma.\n* All subjects have to be able to provide written informed consent.\n\nExclusion Criteria:\n\n* Patients with lesions, primary or secondary, that are so small that a punch biopsy for the study would risk affecting the histopathological diagnosis.",{"count":207,"type":21},2000,"The investigators' hypothesis is that cutaneous melanoma, melanoma in situ, dysplastic nevi and benign nevi all differ in not only clinical characteristics but also molecular and genotypic characteristics.\n\nPatients with suspected primary cutaneous melanoma or a differential diagnosis, or secondary melanoma can be asked to participate in the first part of the project and patients with suspected or confirmed secondary (spread) melanoma can be included in the second part of the study. Participants included in the study answer a validated questionnaire regarding epidemiological and phenotypic factors to map medical history, prior UV exposure, family history of melanoma and\u002For other cancer types, skin type, smoking habits, alcohol use and quality of life.\n\nBlood samples (whole blood) are collected before primary local excision and before secondary surgical procedures as well as during follow up of patients with secondary disease and oncologic treatment. During local excision of the primary pigmented skin lesion, full-thickness skin punch biopsies are taken by trained dermatologists. The biopsies, in the lesion and next to the lesion in the normal skin of the suspected melanoma, are taken, snap frozen and stored deep frozen. The primary lesions are documented by accurate imaging methods prior to excision.\n\nTissue samples from suspected or confirmed secondary melanomas are collected mainly through surgical and core needle biopsies before, during and after treatment and in case of disease progress or treatment failure. Tissue samples are snap-frozen and stored in the same way as samples from primary melanomas.\n\nComprehensive questionnaire based, imaging-based information, as well as histologic information provided from the pathologist report is included and stored in a secure database.\n\nAll the information in the database, along with information from molecular analysis of tissue and\u002For blood samples will then be used to find objective, molecular and clinical differences in melanoma, melanoma in situ, dysplastic and benign nevi along with potential information of biological aggressivity of both primary and secondary melanoma in order to find more objective diagnostic markers.",[210,211,212,213,28,214],"Melanoma","Melanoma in Situ","Dysplastic Nevi","Mole (Dermatology)","Mutation",[216,210,217,218,219,220,221,222,223,224],"Biobank","nevus","mole","dermoscopy","dermatoscopy","skin cancer","Sequence analysis, DNA","Sequence analysis, RNA","Whole genome sequencing","2024-01-22",{"date":227,"type":34},"2024-01-23",{"date":229,"type":34},"2013-11-04",{"date":231,"type":21},"2028-12",{"name":233,"class":41},"Region Skane",4,{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":17,"minAge":243,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":83,"phases":246,"briefSummary":248,"conditions":249,"keywords":252,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":42},"100530123","concurrent-oct-and-ffr-guided-pci-in-cad-100530123","NCT06182683","Concurrent OCT and FFR-guided PCI in CAD","Concurrent OPTIcal Coherence Tomography and frActional Flow REserve-guided Therapeutic Intervention in Patients With Coronary Artery Disease (OPTICARE-CAD)","OPTICARE-CAD","Inclusion Criteria:\n\n1. Age greater than 19 years old\n2. Patients undergoing coronary stent implantation for stable angina or acute coronary syndrome\n3. Patients provided on informed consent\n\nExclusion Criteria:\n\n1. Individuals with a history of increased bleeding tendencies or hematologic disorders\n2. Presented with refractory cardiogenic shock\n3. Individuals with a history of stent thrombosis\n4. Expected life expectancy of less than 1 year\n5. Left ventricular ejection fraction (LVEF) ≥ 20%\n6. Women who are breastfeeding, pregnant, or planning to become pregnant\n7. Deemed unsuitable for participation by the investigator\n8. Patients unwilling to participate in the clinical trial","19 Years",{"count":245,"type":21},700,[247],"NA","The present study is a prospective randomized clinical trial aimed to compare the therapeutic strategy of angiography-guided versus concurrent OCT\u002FFFR-guided intervention in patients with coronary artery disease.",[250,28,251],"Coronary Artery Disease","Atheroscleroses, Coronary",[253,254,255,256,257,258],"Optical coherence tomography","Fractional flow reserve","Angiography","Coronary artery disease","Percutaneous coronary intervention","Drug-eluting stent","2023-12-25",{"date":261,"type":34},"2023-12-27",{"date":263,"type":34},"2023-11-30",{"date":265,"type":21},"2029-12-31",{"name":267,"class":41},"Korea University Guro Hospital",{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":275,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":277,"conditions":278,"keywords":281,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":293,"locationsCount":296},"100518800","ai-prediction-of-gastric-cancer-response-to-neoadjuvant-chemotherapy-100518800","NCT06035250","AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy","Deep Learning-Based Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy","Inclusion Criteria:\n\n* Age 18 years or older;\n* Pathologically diagnosed with advanced gastric cancer in accordance with the American AJCC's TNM staging standards;\n* Have not undergone any systematic anti-cancer treatments before neoadjuvant chemotherapy and have not had surgery for local progression or distant metastasis;\n* Received standard neoadjuvant chemotherapy as recommended by the clinical guidelines, and have documented treatment details;\n* CT imaging and biopsy pathology images strictly taken within one month prior to starting neoadjuvant treatment;\n* Patients possess comprehensive preoperative clinical information and post-operative TRG grading.\n\nExclusion Criteria:\n\n* Patients whose CT or pathology images are unclear, making lesion assessment infeasible;\n* Patients diagnosed with other concurrent tumors.",{"count":276,"type":21},200,"This study seeks to develop a deep-learning-based intelligent predictive model for the efficacy of neoadjuvant chemotherapy in gastric cancer patients. By utilizing the patients' CT imaging data, biopsy pathology images, and clinical information, the intelligent model will predict the post-neoadjuvant chemotherapy efficacy and prognosis, offering assistance in personalized treatment decisions for gastric cancer patients.",[279,28,280],"Gastric Cancer","Pathology",[279,282,283,284,285,286],"Neoadjuvant Chemotherapy","Radiomics","Treatment Outcome Prediction","Pathomics","Radiopathomics","2023-09-26",{"date":289,"type":34},"2023-09-28",{"date":291,"type":34},"2023-09-10",{"date":265,"type":21},{"name":294,"class":295},"Chinese Academy of Sciences","OTHER_GOV",22,"IMAGE"]